Evidence map›Paper›PMID 40386954›Full record

Observational studyAustralasian journal on ageing2025

Frailty and prescriptions of secondary prevention medications in older people with diabetes and coronary heart disease-An observational study in Vietnam.

Wei Jin Wong, Tan Van Nguyen, Irum Farooq, Ying Zhang, Christopher Harrison, Kit Mun Tan, Katie Harris, Mark Woodward, Tu Nguyen

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Australasian journal on ageing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wei Jin WongSydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
Tan Van NguyenHo Chi Minh City Faculty of Medicine, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam.ORCID https://orcid.org/0000-0002-0234-6596
Irum FarooqSydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
Ying ZhangSydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
Christopher HarrisonSydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
Kit Mun TanUniversiti Malaya, Kuala Lumpur, Malaysia.
Katie HarrisThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Mark WoodwardThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Tu NguyenSydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study sought to quantify the prevalence of frailty among type 2 diabetes (T2D) patients with coronary heart disease (CHD) and examine the relationship between frailty and the prescription of secondary prevention medications.

methodsA prospective observational study was conducted at a tertiary hospital in Vietnam from November 2022 to June 2023. Patients aged 60 years or above with T2D and CHD were included for analysis. Multivariable logistic regression was applied to examine the association between frailty and the prescription of secondary prevention medications: antiplatelets, statins, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ACEIs/ARBs). Frailty was measured using the Clinical Frailty Scale (CFS) version 2.0.

resultsThere were 274 participants included in this analysis. Participants had a median age of 72.0 years, 28% were female and 59% were frail. The prescription rates of cardiovascular medicines for frail versus non-frail participants were as follows: antiplatelets (66% vs. 94%, p < .001), statins (96% vs. 92%, p = .21), beta-blockers (81% vs. 88%, p = .13), ACEIs/ARBs (75% vs. 81%, p = .22) and for all four types (42% vs. 64%, p < .001). In the multiple adjusted regression models, increased CFS score was associated with reduced prescriptions of beta-blockers, ACEIs/ARBs and all four types of medications.

conclusionsFrailty was common among older Vietnamese patients with CHD and diabetes, and significantly affected the prescription of secondary prevention medicines. Future research should explore the link between frailty and secondary prevention medicines in a larger, more diverse population.

Indexed as

Cardiovascular AgentsCoronary DiseaseDiabetes Mellitus, Type 2Frail ElderlyFrailtySecondary PreventionAgedAged, 80 and overAge FactorsDrug PrescriptionsFemaleHumansMaleMiddle AgedPrevalenceProspective StudiesCardiovascular Agentscardiovascular diseasefrailtyprescriptionssecondary preventionVietnam

Identifiers

PMID40386954
PMCPMC12086956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.